831P - Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Anticancer Agents
Renal Cell Cancer
Biological Therapy
Presenter Victoria Neiman
Citation Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373
Authors V. Neiman1, D. Keizman2, D. Sarid3, J. Lee4, A. Sella5, M. Gottfried2, H. Hammers6, M. Eisenberger6, M. Carducci6, V. Sinibaldi6, E. Rosenbaum1, A. Peer7, A. Neumann7, W. Mermershtain8, K.R. Rouvinov8, R. Berger9, I. Yildiz10
  • 1Clinical Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 49100 - Petach Tikva/IL
  • 2Oncology, Meir Medical Center, Kfar Saba/IL
  • 3Oncology, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv/IL
  • 4Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 5Oncology, Asaf Harofeh Medical Center, Zerifin/IL
  • 6Oncology, Johns Hopkins Hospital, 21231 - Baltimore/US
  • 7Oncology, Rambam Health Care Center, Haifa/IL
  • 8Oncology, Soroka University Medical Center, 84101 - Beer Sheva/IL
  • 9Oncology, Chaim Sheba Medical Center, Ramat Gan/IL
  • 10Oncology, Ataturk Training and Research Hospital,Izmir Katip Celebi University, Izmir/TR



Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe RCC (mchRCC), is limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients, in terms of outcome and comparison to mccRCC.


Records from mchRCC patients treated with first line sunitinb in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC pts were individually matched to mccRCC pts. We compared the clinical benefit rate (CBR), progression free survival (PFS), and overall survival (OS) between the groups.


Between 2004-2014, 36 patients (median age 64, 47% male) with mchRCC were treated with first line sunitinib. 78% achieved a clinical benefit (partial response + stable disease). Median progression free survival (PFS) and overall survival (OS) were 10 and 26 months, respectively. Factors associated with PFS were the HENG risk (HR 3.3, p = 0.03) and pre-treatment neutrophil to lymphocyte ratio (NLR) >3 (HR 0.63, p = 0.02). Factors associated with OS were the HENG risk (HR 4.1, p = 0.04), liver metastases (HR 3.8, p = 0.03), and pre-treatment NLR 


In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The HENG risk and pre-treatment NLR may be associated with PFS and OS.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.